Bupropion/zonisamide

Bupropion/zonisamide (planned trade name Empatic) is an experimental combination drug combination for the treatment of obesity.
It is being developed by Orexigen Therapeutics. It is currently at phase II testing. The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments. When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo. 
Empatic was called Excalia before its name was changed.